Novo Nordisk recently announced positive results from the kidney outcomes trial FLOW.

According to the trial, Ozempic (semaglutide) 1.0mg reduced the risk of kidney disease progression and the risk of kidney and cardiovascular deaths by 24%.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Key opinion leaders (KOLs) interviewed by GlobalData, a leading data and analytics company, have emphasised that unmet needs in the kidney disease space include next-generation therapies with alternate mechanisms of action and enhanced clinical profiles.

If approved, Ozempic will become the first glucagon-like peptide-1 (GLP-1) therapy option for patients with Type 2 diabetes (T2D) and chronic kidney disease (CKD).

FLOW was a randomised, double-blind, placebo-controlled, parallel-group, Phase III trial to assess the safety and efficacy of semaglutide when added to the standard of care; 3,533 participants with T2D and CKD were enrolled and the safety and tolerability profiles were consistent with previous semaglutide 1.0mg studies.

See Also:

According to KOLs, Ozempic could be an excellent option for patients who are diabetic and obese.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, KOLs believe that Ozempic has the potential to be a treatment option for non-diabetic CKD patients whose kidney problems are due to their obesity as opposed to diabetes.

The ageing global population will lead to an increase in the prevalence of CKD, leading to an expansion of the market, as well as a growing need for more therapeutic options.

However, the widespread use of generic CKD drugs continues to make it difficult for high-priced branded therapies to fully penetrate the market.

Ozempic is a GLP-1 receptor agonist and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D.

It is formulated as an injectable solution for a subcutaneous route of administration.